Refine by
Brain Tumor Articles & Analysis
26 articles found
This combined entity is able to cross the blood-brain barrier (BBB) and blood-brain tumour barrier (BBTB) with systemic injection, and to be targeted to glioma lesions. ...
These advancements not only enhance our understanding of the disease but also pave the way for more targeted therapeutic solutions. Tumor models for breast cancer, which include both in vivo and in vitro systems, are crucial for studying the complexities of tumor biology and testing potential treatments. ...
Alfa Cytology has introduced its advanced drug development services for brain tumors. Alfa Cytology, celebrated for its cutting-edge biotech solutions and extensive tumor research expertise, has recently introduced brain tumor drug development services, designed to empower researchers in understanding the ...
Brain tumors can be broadly categorized into primary and secondary (or metastatic) tumors. ...
For instance, PEGylated liposomes and nanoparticles can be engineered to carry anticancer drugs directly to tumor sites. The EPR (enhanced permeability and retention) effect allows these PEGylated carriers to accumulate in tumor tissues, increasing the local concentration of the drug and reducing systemic side effects. Doxil®, a PEGylated liposomal ...
While it was first discovered in gliomas (a type of brain tumor), TNC protein is present in a variety of tissues, especially during embryonic development and tissue remodeling after injury. ...
With professional knowledge of PC (particularly intra-tumor heterogeneity, TME crosstalk, and micro-environmental instability) and powerful cross-platform collaboration capability, Alfa Cytology has launched a series of PC vaccine development services to meet pre-clinical research needs. ...
The induction of MMPs activity contributes to the disassembly of intercellular junctions and the degradation of ECM, thus overcoming the physical limitations of cell motility and participating in tumor invasion. Thus, they are also targets of antitumor drugs. MMPs are involved in processes such as osteoblast/osteoclast differentiation, bone formation, osteolysis of osteoid ...
Ongoing research and inventions in the field of oncology focus on the development of small molecule drug therapies for use in brain tumor resection. Small molecule drugs are being developed to target and effectively treat brain tumors to improve therapeutic outcomes. ...
Benefits and advantages of iPSC differentiation to neural stem cells (NSC), neurons and glial cells: Provides genetic and physiologically relevant in vitro models to study neural development and associated disorders: congenital disorders, neurodegenerative disorders and brain tumors. Generates a valuable model for identifying new targets for neuro-regeneration ...
An article on the rapid identification of pediatric brain tumors using DMS was published in Frontiers in Oncology, section Neuro-Oncology and Neurosurgical Oncology! The results show that most common pediatric brain tumor samples can be differentiated with DMS. DMS shows promise in becoming and additional instrument for ...
Consequently, WES has become the preferred approach for comparing tumor-normal samples. Tumor Mutational Burden (TMB) Analysis using WES Tumor Mutational Burden (TMB) quantifies the number of somatic mutations per megabase (MB) of the longest transcript sequence. Although TMB shows potential as a biomarker for immunotherapy in solid ...
Glioblastoma is a deadly brain cancer with a dire prognosis. Unlike most cancers, it still grows in the presence of the p53 protein. ...
The use of Quantitative Susceptibility Mapping (QSM) is often viewed as incompatible with current standard radiology workflows. Some radiologists or departments may be unaware of its existence or purpose. Despite the skepticism surrounding its viability in a clinical setting, QSM shows great potential in a wide range of clinical applications, particularly for biomarker detection and ...
It’s been about a year since I started my PhD project named The Toxicity Atlas. In this four-year project, I’m collaborating with researchers from Amsterdam UMC and my colleagues at Medstone to find better treatment options for patients with brain cancer. Let me tell you more about my results so far. Information databases Developing new drugs costs a lot of money and a lot of ...
Glioblastoma multiforme (GBM) is a deadly type of brain tumor and 5-year survival is just 8% for those aged 45-54. About 25% of GBM patients are not actively treated due to rapid disease progression. ...
For select indications including many primary and metastatic brain tumors, stereotactic radiosurgery (SRS) is proven to be an effective alternative to invasive surgeries. ...
CURRENT STANDARD OF CARE FOR BRAIN TUMORS The current initial standard of care for aggressive brain tumors—whether they are primary brain tumors (ie, tumors that originate in the brain), or metastatic tumors from cancers that started ...
CURRENT STANDARD OF CARE The current initial standard of care for aggressive brain tumors—either primary brain tumors (ie, tumors that originate inside the brain) or metastatic tumors (ie, tumors from cancers that originate outside of the ...
“With our shared vision for advancing the field of radiosurgery for the brain, we are looking forward to introducing the globally recognized ZAP-X in ...